ArticlePDF AvailableLiterature Review

Arnica montana L. - a plant of healing: Review

  • Guru gobind singh college of pharmacy,yamunanagar

Abstract and Figures

Objectives: Arnica montana is a widely used therapeutic plant used traditionally to treat various ailments. The objective of this study was to evaluate the botany, phytochemistry and ethnopharmacology along with special emphasis given on pharmacological activity of plant A. montana. Key findings: The plant extracts have been reported to possess antibacterial, antitumor, antioxidant, anti-inflammatory, antifungal and immunomodulatory activity. A wide range of chemical compounds including sesquiterpene lactones and their short-chain carbonic acid esters, flavonoids, carotenoids, essential oils, diterpenes, arnidiol, pyrrolizidine alkaloids, coumarins, phenolic acids, lignans and oligosaccharides, etc., are found in different parts of the plant. Summary: It has been scrutinized that extensive research has been carried out to explore the therapeutic potential of flowers of the plant. Therefore, investigations should be carried out to explore the therapeutic potential of other parts of the plant for better therapeutic utilization.
Content may be subject to copyright.
Arnica montana L. a plant of healing: review
Priyanka Kriplani
, Kumar Guarve
and Uttam S. Baghael
Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana,
I.K. Gujral Punjab Technical University, Jalandhar, Punjab, and
Department of
Pharmaceutical Sciences, Khalsa College, Amritsar, Punjab, India
Arnica montana; anti-inflammatory;
helenalin; sesquiterpene lactones
Priyanka Kriplani, Department of
Pharmaceutical Sciences, Guru Gobind Singh
College of Pharmacy, Yamunanagar,
135001 Haryana, India.
Received January 17, 2017
Accepted March 4, 2017
doi: 10.1111/jphp.12724
Objectives Arnica montana is a widely used therapeutic plant used traditionally
to treat various ailments. The objective of this study was to evaluate the botany,
phytochemistry and ethnopharmacology along with special emphasis given on
pharmacological activity of plant A. montana.
Key findings The plant extracts have been reported to possess antibacterial, anti-
tumor, antioxidant, anti-inflammatory, antifungal and immunomodulatory
activity. A wide range of chemical compounds including sesquiterpene lactones
and their short-chain carbonic acid esters, flavonoids, carotenoids, essential oils,
diterpenes, arnidiol, pyrrolizidine alkaloids, coumarins, phenolic acids, lignans
and oligosaccharides, etc., are found in different parts of the plant.
Summary It has been scrutinized that extensive research has been carried out to
explore the therapeutic potential of flowers of the plant. Therefore, investigations
should be carried out to explore the therapeutic potential of other parts of the
plant for better therapeutic utilization.
Asteraceae, also known as the aster, daisy, composite or
sunflower family, is one of the largest flowering plant fam-
ily containing about 1600 genera and more than 23 000
species and 13 subfamilies.
Medicinally important
compounds for curing various ailments are found in some
genera, e.g. species of Arnica, Centaurea granatensis Boiss.,
Conyza bonariensis and Senecio doronicum, which are
reported for the treatment of variety of ailments.
aceae’ name is give after one of the genus of this family, i.e.
‘Aster’, which is derived from the Greek word rsήq
which means star that denotes its inflorescence. Synan-
therology is the name given to the study of this family. As
its petals open in the morning and close in the evening,
members of this family are also called ‘Daisy’, which is
derived from English name: daegesege, which means ‘day’s
The plants of this family grow as annual and peren-
nial herbs and shrubs, vines or trees in forests to high-alti-
tude grasslands.
Characteristic inflorescences (flowers in
dense heads with involucrum) and the calyx forming a pap-
pus crowning the nut are found in this family.
A. mon-
tana (Asteraceae) is a high-altitude perennial plant
indigenous to mountain slopes in Europe, northern Asia,
Siberia and America also known as fall-kraut, leopard’s
bane, sneezewort and mountain tobacco
and had proved
to be an important medicinal plant.
Occurrence, botanical description and
Arnica montana is used since centuries in homoeopathic
system of medicine. It is used for the treatment of 66 differ-
ent pathological conditions, but frequently used for contu-
sion, wounds, rheumatism and inflammation. In early
medieval texts, the name Arnica was not referred any-
where. This name was given in 1533 by the St, Hildegard’s
‘Physica’ editor which was further used in 16th century by
Dalechamps, who thought it was derived from Greek word
Ptarmika which means something that causes sneezing,
and Haller and Linnaeus were the first people to use the
name Arnica in both pharmacy and botany. In northern
Spain, Arnica montana L. was named as: bet
onica de los
montes’, tobaco de montana’, talpa’or‘talpica’, and in
1785, the plant was successfully used in hospitals for the
treatment of loss of vision that occurs without an apparent
lesion affecting the eye also called as amaurosis.
The 32 species known as Arnica’ belong to six botanical
families and five subgenera. Of this, 24 species are Aster-
aceae that belong to eight tribes as follows:
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 925
Anthemideae Cass. (Achillea ageratum L.).,
Astereae Cass. (Conyza bonariensis (L.) Cronquist),
Cardueae Cass. (Centaurea granatensis Boiss. ex DC.).,
Cichorieae Lam. &DC. (Andryala integrifolia L., A. ragu-
sina L., Crepis paludosa (L.) Moench, C. vesicaria L. subsp.
taraxacifolia (Thuill.) Thell. and Hieracium sp.).,
Doroniceae Panero (Doronicum carpetanum Boiss. & Reut.
Ex Willk. &Lange, D. grandiflorum Lam. and D. parda-
lianches L.).,
Inulaeae Cass. (Chiliadenus glutinosus (L.) Fourr, Dit-
trichia vis- cosa (L.) Greuter, Inula britannica L., I. hele-
nioides DC, I. helvetica
Weber, I. Montana L., I. salicina L., Asteriscus spinosus
(L.) Sch. Bip., Pulicaria odora (L.) Rchb., and P. paludosa
Madieae Jeps. (A. montana L.).,
Senecioneae Cass. (Senecio doronicum (L.) L., S. jacobaea
L., and S. pyrenaicus L.).,
and the subgenera are Arctica,
Andropurpurea, Austromontana, Montana and Chamisso-
The flowers of the plant are traded by the following
pharmaceutical trade names, i.e. Arnica flos (latin), Fleur d
‘Arnica’ (Fr), Flor de
arnica (Sp), Arnikabl
uten (Ge) and
Fiore de Arnica (It), and the trade names for the dried roots
are Arnikawurzel (Ge), Arnicae radix (latin), Raiz de Arnica
(Sp) and Racine d ‘Arnique’ (Fr). However, this species is
considered endangered in different European countries like
Bosnia-Herzegovina, Croatia, Slovenia, Germany and
Lithuania, Luxembourg, Sweden, Romania, Balkans, Spain
and Hungary, so in order to protect this species, its cultiva-
tion is increasing but its harvest is not allowed in most
European countries including Italy.
The plant grows
best at an altitude of 5002500 m in less fertile meadows
and on acidic soils in alpine meadows and peat bogs health-
lands. A. montana L. (Asteraceae) is an herbaceous, peren-
nial, 12 ft tall plant, with dark green basal, lower cauline
leaves (obovate or elliptical to oblanceolate), hairy stems
and bright yellow daisy-like ray flowers. The ray flowers’
teeth size is as <1 mm long or between 1 and 2 mm long.
The second flowers’ diameter varies between 4.9 and
5.7 cm. The flowers appear in July and August with 17
flower heads.
The best harvesting time for the flowers
including the calyx in the Northern Hemisphere is June
August; however, in central Otago, New Zealand, it is
DecemberJanuary and for the roots, it is in spring (April)
and autumn (October). The fresh flowers are used to pre-
pare tincture, or they may be dried before in warm shady
area with proper air circulation to prepare tincture. Its fruit
is like a seed with white or pale tan bristles and has a pap-
pus of plumose. Seeds are of cylindrical shape. Plants are
germinated by division from cuttings in the spring or by
A. montana seed; however, seed germination is below 80%
and may take about a month or as long as 2 years to germi-
nate. Seeds are sown in the late summer by lightly covering
them and spaced 30 cm apart. Plants may be grown indoor
by sowing in pots at 13 °C for 1 year and then transplant-
ing them outdoor after last frost. These are cut before flow-
ering to keep stems short and after flowering to produce
secondary bloom.
The plant possesses numerous medicinal activity. The
flowers of the plant show greater medicinal value and are
used as antiphlogistic, inotropic, antibiotic, anti-inflamma-
tory, immunomodulatory, antiplatelet, uterotonic, anti-
rheumatic and analgesic in febrile conditions.
oral administration of flowers in the form of fresh plant
mother tincture and local external application in the form
of cream, ointment or gel or in the form of wet poultice
comprising of a solution that contains one tablespoon of
A. montana tincture to a quarter litre of light warm water
have been valued for curing osteoarthritis, alopecia and
chronic venous insufficiency.
According to European
pharmacopoeia (1809), A. montana tincture is produced
from A. montana flowers with 0.04% sesquiterpene lac-
tones expressed as dihydrohelenalin tiglate. The tincture
contains one part of the drug in 10 parts of ethanol (60%
(V/V) to 70% (V/V)). According to European Union, her-
bal preparation(s) containing A. montana are tincture
(1 : 10) extracted with ethanol 70% v/v, tincture (1 : 5)
extracted with ethanol 60% v/v and liquid extract (1 : 20)
extracted with ethanol 50% m/m, mainly of flowers. Tinc-
ture is dried by evaporation, and the extract is incorporated
in numerous herbal drug products.
A. montana has
proved its worth as anti-inflammatory agent. A. montana
extract (330%) when blended with one or more therapeu-
tic or pharmaceutical agents, i.e. camphor, menthol,
eucalyptus oil, mint oil, guaifenesin, topical analgesics,
non-steroidal anti-inflammatory drugs or either transder-
mal opioid analgesics in a petroleum base or pluronic
lecithin organogel, reduces inflammation.
reported that post-traumatic bruising of skin or post-
surgery, postlaser treatment effects can be prevented by
applying ointment containing A. montana (3040%) in a
petrolatum base to the affected area of the skin.
In Videki et al., US patent No. 5043153, compositions
are prepared for the treatment of parodonthopathy and in
Marissal et al., US patent No. 4684522, a cosmetic formula-
tion possessing anticellulitis and slandering activity com-
prising of required content of extracts of various plants
such as Hedera haelix L.,A. montana L. (containing gly-
cols), Aesculus hipocastanus L., Ruscus aculeatus L., extract
containing saponins and kola nut extract containing caf-
feine has been reported.
In another study, by Ayache et al., US patent No.
4795638 revealed a cosmetic preparation for reducing or
eliminating cellulite or fat build-up containing an oily base,
a rubefacient (extracts of capsicum; nicotinic acid salts like
triethanolamine nicotinate; nicotinic acid esters like
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945926
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
methyl, ethyl, hexyl, phenyl and benzyl nicitinate and alpha
tocopherol nicotinate; nicotinyl alcohol and its organic acid
esters like nicotinate and nicotinyl tartarate), one oil sol-
uble plant extract of either climbing ivy, A. montana, mari-
gold, rosemary, ginseng, sage, ruscus, Saint Johns wort,
ulmaria, algae, a volatile polysiloxane and orthosiphon.
Paradise L. in US patent No. 5795573 A has concluded that
homoeopathic topical anti-inflammatory preparations con-
taining synergistic combination of extracts from A. mon-
tana, Rhus toxicodendron and Aesculus hippocastanum and
belladonna can be used to treat muscular cramps, soreness
and pain. In many inflammatory diseases in order to relieve
pain or mask pain caused by kinins and kallakreins, it is
desirable to promote healing and improve circulation to
tissues nerves. US patent No. 5162037 to Whitson-Fisch-
man discloses a homoeopathic mixture to treat pathogenic
conditions of body containing one herb or herbal extract of
A. montana, Rhus Toxicum, pineal gland and a magnetically
permeable substance.
Arnica in combination with Ruta
graveolens, Aconitum napellus, Bellis perennis, Hamamelis
virginiana, Hypericum perforatum, Calendula officinalis,
Ledum palustre, Bryonia alba is effective for treating
Recently, Bilia has reported that both the tincture and
the dried extract of the plant are physically incompatible
and unstable when formulated as semisolid formulations as
well as contain very less content of sesquiterpene lactones.
Therefore, he introduced a pioneering supercritical carbon
dioxide extract, analysed by both HPLC and NMR spec-
troscopy containing 9.5%(w/w) of sesquiterpenes. It can be
a good substitute for the topical semisolid preparations
available in the market.
Roots of A. montana contain
thymol, which is used for flavouring purposes, as antioxi-
dant in foodstuffs and beverages and also as fungicide,
preservative and insecticidal agent.
Roots of the plant
are also used as bacteriostatic, antiphlogistic, choleretic and
cholagogic due to presence of polyacetylenic compounds,
phenol esters and phenolcarboxylic acids.
Alcoholic or
isopropanolic extract of A. montana flowers in the form of
liquid formulations such as syrups, tinctures and ointments
is used for the treatment of cattle, sheep, horses, swine and
goats for inflammation of udder, joints, tendons, skin;
eczema and to cure wounds of mucous membrane and
A. montana in combination with Echinacea angus-
tifolia, Eupatorium perfoliatum and Baptisia tinctoria is used
to treat upper respiratory infections.
homoeopathic preparations of the plant are available in the
market such as Hyland’s Arnicated hair oil, shampoo,
Arnica ointment, Arnica tablets and pellets [69,129,309,
30CH, 200CH], Hyland’s Arnica spray as the plant pos-
sesses various activities. Bioactive constituents such as
sesquiterpene lactones, i.e. helenalin an 11a,13-dihydohele-
nalin, phenolic acids and flavonoids, have been isolated by
various chemical and pharmacological analyses of the plant
which acts as anti-inflammatory agent, antioxidant,
antiphlogistic, immunomodulatory and used to treat vari-
ous ailments like osteoarthritis. Cosmetic, pharmaceutical
and nutraceutical utility of A. montana ethanolic seed
extract has been reported in combination with other plant
active constituents or either alone. It has also been reported
in literature that decoction, infusion or macerated extracts
of A. montana flowers, leaves or aerial parts of the plant
can be used to treat numerous ailments such as bowels
ache, cough, contusion, cuts, haematoma, headache and
As recognized in US Pat. No. 4569839, A. montana also
has soothing and healing properties for the hair and skin.
As taught in US Pat. No. 3832343 by Majoie et al., perhaps
the most common topical use for A. montana is in the
treatment of haematomas as it prevents coagulation of
blood. In US patent No. 4938960 to Ismail, extract of
A. montana promotes blood circulation and is therefore
used for treatment and protection of the skin on the theory
that the A. montana will increase the action of the vitamin
E in the composition.
One hundred and fifty therapeutically active substances are
present in A. montana plant, i.e. sesquiterpene lactones, i.e.
helenalin,11a,13-dihydohelenalin and their short-chain car-
bonic acid esters (0.31% of dry weight in the flower heads,
0.10.5% in leaves), flavonoids (0.61.7%) by micellar elec-
trokinetic capillary chromatography
in the form of fla-
vonoid glycosides, flavonoid glucuronides and flavonoid
aglycones; essential oils, composed thoroughly of fatty
acids, thymol derivatives, monoterpenes and sesquiterpene.
Other constituents of A. montana are carotenoids; diterpe-
nes; arnidiol (a triterpene); pyrrolizidine alkaloids (tussi-
lagine and isotussilagine)
; polyacetylenes; coumarins
(umbelliferone and scopoletin); phenolic acids (chlorogenic
acid, caffeic acid and cynarin, 1.02.2%)
; lignans; dicaf-
feoyl quinic derivatives (1,3- 3,5 and 4,5 dicaffeoyl quinic
acids); and oligosaccharides.
It contains sesquiterpene
lactones being metacryl, isobutyryl, tygloyl, methacryloyl,
isovaleryl helenalin derivatives,
apigenin, luteolin, hispi-
dulin, quercetin and kaempferol glycosides in high quanti-
ties. Phytochemical study of A. montana notifies that the
nature and amount of phytochemicals such as caffeic acid
derivatives, phenolics and helenalin esters and dihydrohele-
nalin esters present in the flower heads vary according to
climatic conditions (i.e. temperature and rainfall) and alti-
tudinal variations. It has been investigated by many
researchers that flowers of the plant are mainly rich in
active constituents.
The content and nature of
sesquiterpene lactones vary with altitude. The flowers
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 927
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
collected from high-altitude healthlands contain principally
helenalin esters while the flowers from lower altitude mead-
ows contain dihydrohelenalin esters in large amount. In
another study, the effect of ecological factors has been
investigated on the content of sesquiterpene lactones in 10
German healthlands. Higher content of sesquiterpene lac-
tones (0.591.10%) was found in the flower heads collected
from the foothills of the Alps.
The phytochemistry of different parts of plant is
discussed below.
Whole plant (Arnicae planta tota)
Various analytical methods such as gas chromatography
with mass selective detection (GC-MSD), spectrophoto-
metric, reverse-phase liquid chromatography (RPLC) and
proton nuclear magnetic resonance spectroscopy
(1HNMR) have been used for analysing the quantity of
lactones present in the plant.
Geographical range
has significant effect on the ratios of helenalin and dihy-
drohelenalin esters of A. montana: helenalin esters are
mainly present in central European collections, while
dihydrohelenalin esters are present principally in Spanish
collections. Pulhmann et al. in 1991 has reported that
methylation analysis, partial acidic and enzymatic hydrol-
ysis and 13C NMR spectroscopy have been used for the
identification of two homogeneous polysaccharides from
cell cultures of A. montana, an acidic arabino-3, 6-galac-
tan-protein with mean molecular weight of 100 000 and a
neutral fucogalactoxyloglucan with mean molecular
weight of 22 500 isolated by DEAE-Sepharose CL-6B and
Sephacryl S-400 column chromatography.
Arnica montana flowers (Arnicae flos)
In 1992, Paßreiter et al. stated that Arnica flower consti-
tutes various constituents such as flavonoids (0.40.6%),
sesquiterpenes, acetylenes, hydroxycoumarines and phenyl
acrylic acids and essential oil (0.20.35% in flower heads
and 0.20.5% in leaves), phenolcarbonic acids [such as
chlorogenic acid (5-o-caffeoylquinic acid), cynarin 1,3-di-
O-caffeoylquinic acid, caffeic acid) (Figure 1) by TLC and
HPLC, umbelliferone, scopoletin (Figure 2), 2-pyrrolidi-
neacetic acid and C-1 epimers of the two pyrrolizidine
acids and after Soxhlet extraction by methanol traces of
pyrrolizidine alkaloids (tussilagin and isotussilagin) (Fig-
ure 3) have also been isolated.
The flowers of
Arnica species contain especially different sesquiterpene
lactones which have a pseudo-guajonolide structure,
which often may occur as ester derivatives such as 2,3-
dihydroaromaticin, chamissonoid, mexicanin 1 (Fig-
ure 4).
The total amount of sesquiterpene lactones vary
with maturity of dry flowers; i.e. the amount increases
from 0.5% in buds to 0.9% in withered flowers. Sesquiter-
pene lactones are reported as good anti-inflammatory and
cytotoxic agents.
Dziki in 2009 reported that seeds contain mainly phenolic
acids (chlorogenic, caffeic acid, quercetin and kaempferol)
(Figure 5) and flavonoids (luteolin and apigenin) (Fig-
ure 6), respectively, as active principles.
Aiello in 2014
reported that the seed yield can be increased with years of
cultivation if regularly fertilizers are added.
OCaf f eoyl
OCaf f e oyl
OCaff eoyl
1,5 di-o- caffeoylquinic acid 1,4,5-tri-o-caff eoylquinic acid
Chlorogenic acid
Figure 1 Dicaffeoyl quinic derivatives/ phenolic acids of Arnica montana plant.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945928
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
Roots (Arnicae radix)
Pljevljakusic et al. carried out both quantitative and quali-
tative analyses using GCFID and GCMS and concluded
that the main constituents of rhizome and root oils are aro-
matic compounds, i.e. 2,5-dimethoxyp-cymene (28.9
30.0% and 37.940.6%, respectively) (Figure 7), thymol
methyl ether (26.127.1% and 9.610.6%, respectively)
(Figure 8), pmethoxyheptanophenone (6.18.9% and 7.0
7.5%, respectively) and 2,6-diisopropylanisole (8.910.4%
and 12.814.1%, respectively) (Figure 9) . The essential
oil from roots and rhizome also contains camphene,
phellandrene, limonene, 5p-mentha-2,4(8)diene, terpineol,
carvacrol, methyl ether, p-diisopropyl-benzene, bornyl
acetate, thymol silphiperfol-5-ene, 7-epi-silphiperfol-5-
ene, silphiperfol-6-ene, modheph-2-ene, isocomene, iso-
bornyl isobutanoate, trans-caryophyllene, 2,5-dimethoxy-
para-cymene, trans-bergamotene, 2,6 diisopropylanisole,
cis-farnesene, germacrene, pinchotene acetate, p-methoxy-
heptanophenone, isobornyl 2-methyl butanoate, isobornyl
Umbelliferone Scopoletin
Figure 2 Coumarins of Arnica montana plant.
2-pyrrolidineacetic acid Methyl ester of 2-pyrrolidineacetic aci
Tussilagine C-2 epimer isotussilagine
1- epimer of tussilagine 1- epimer of isotussilagine
Figure 3 Pyrrolizidine Alkaloids of Arnica montana plant.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 929
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
isovalerate, sesquiphellandrene, dimethyl-ionone, lignans
and zierone (Figures 4, 7 and 9). Light microscopy, scan-
ning microscopy and transmission microscopy were used
to study the secretory tissues localized as idioblastic secre-
tory cells in the cortical region of the root and rhizome for
essential oil synthesis.
Petrova reported that the amount
of essential oils varies in different parts of A. montana, from
2.70 to 6.91% in rhizomes and 1.77 to 3.76% in roots. Ken-
nedy in 1998 found that ethanolic extract of roots contains
a panel of non-reducing oligofructosides in later period of
growth and both non-reducing oligofructosides and reduc-
ing inulin-type oligofructosides in early growth period.
In 2011, Weremczuk-Jezyna et al. separated 56 active
principles from the essential oil of which 10-isobutyryloxy-
8,9-didehydro-thymol isobutyrate and 10-isobutyryloxy-
8,9-didehydro-thymol methyl ether were the main
components obtained by hydrodistillation of hairy roots of
the plant (Shown in Figure 3). He carried out image analy-
sis using LEICA DCML microscope having IM1000 (Imagic
Bildverarbeitung AG Software company, Opfikon, Switzer-
land) software and a digital camera.
Arnica montana possesses significant anti-inflammatory,
antibacterial, antifungal antioxidant and immunomodula-
tory activity.
Anti-inflammatory activity
Arnica montana has significant anti-inflammatory potential.
Huber et al. in 2011 disclosed that the molecular mechanism
of sesquiterpene lactones differs from that of non-steroidal
anti-inflammatory drugs, i.e. indomethacin and acetyl
salicylic acid. These lactones significantly decrease NFkap-
paB-mediated inflammation as they pass through the skin
Phosphorylation and degeneration of IkappaB,
NF-kappaB’s inhibitory subunit, stimulates NF-kappaB.
NFkappaB activation by T cells, B cells and epithelial cells is
inhibited by helenalin which in turn blocks kappaB-driven
gene expression. This blockage is precise and is due to alter-
ation of NF-kappaB/IkappaB complex, inhibiting the dis-
charge of IkappaB by helenalin.
Arnica 6c has been
Helenalin 11a,13 dihydrohelenalin
aCH3CO- acetyl
bCH2=C(CH3)CO- a-methacryl
c CH3CH=C(CH3)CO- tigloyl
d (CH3)2CHCO- isobutyryl
e CH3CH2CH(CH3)CO- 2-methylbutyryl
f (CH3)2CHCH2CO- isovaleryl
Trans caryophyllene ß-cis-f arnesene 2, 3 -dihydroaromatici
Germacrene 7-Epi-silphiperfol-5-ene Chamissonoid Mexicanin 1
Figure 4 Sesquiterpene lactones and its derivatives of Arnica montana plant.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945930
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
investigated for its anti-inflammatory potential on car-
rageenin and rat paw oedema induced by nystatin. Arnica 6c
significantly reduced inflammation while in case of his-
tamine-induced oedema, the action of histamine was inhib-
ited and the vascular permeability was increased.
also investigated that when a solution of A. montana 6cH,
dexamethasone or 5% hydroalcoholic solution is injected
into male adult Wistar rats, they show marked anti-inflam-
matory activity. Kawakami et al. in 2011 reported a series of
inflammatory-positive cells, which play a major role in
inflammatory process, i.e. CD54 (ICAM-1), CD18 (BETA 2
integrin), CD45RA (B lymphocytes), CD3 (T lymphocytes),
CD163 (ED2 protein) and MAC 387 (monocytes and macro-
phages). It was concluded that rats that presented oedema
after a long time exhibited minor oedema, less degranulation
of mast cells and increase in diameter of lymphatic vessels.
In another study, it was concluded that acute non-fibrosed
mastitis can be effectively treated with Arnica 30CH when
taken orally in combination with Healwell VT-6 (comprising
of Calcarea fluorica 200CH, Conium 30CH, Silicea 30CH, Phy-
tolacca 200CH, Belladonna 30CH, Ipecacuanha 30CH and Bry-
onia 30CH).
It has also been reported by Sandra et al.,
that A. montana when administered with herbs like Rue, Wil-
low bark, St. John’s Wort and Comfrey treats by improving
musculoskeletal healing in case of deep-rooted complaints like
arthritis or mainly in the first 2448 h of an accident.
Anti-osteoarthritic activity
Widrig et al. in 2007 prepared a topical A. montana gel
containing helenalin, 11_,13-dihydrohelenalin and its ester
that shows significant antiosteoarthritic activity by blocking
the transcription factor NF-aB and NF-AT. It promotes
functional capacity of hands and reduces the time period
and extent of morning stiffness, intensity of pain and the
number of painful joints.
Immunomodulatory activity
Polysaccharide fraction of A. montana flowers are reported
to show significant immunostimulating properties (in-
crease of phagocytosis by granulocytes).
DEAE-Sepharose CL-6B and Sephacryl S-400 column
chromatographic techniques were used to isolate two
Kaempferol 3-O-glucoside 6-methoxy-kaempferol 3-O-glucoside Hispidulin
Quercetin 3-O-glucoside Patuletin 3-O-glucoside Quercetin 3-O-glucuronic acid
Kaempferol Quercetin 6-methoxykaempferol Patuletin
Figure 5 Flavonols of Arnica montana plant.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 931
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
Apige nin Luteolin
Hispidulin Eupafolin
Figure 6 Flavones of Arnica montana plant.
Phellandrene Limonene Camphene
2,5-dimethyl-p-cymene Carvacrol ß- Sesquiphellandrene
Figure 7 Terpenes of Arnica montana plant.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945932
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
polysaccharides from cell cultures of A. montana, i.e. an
acidic arabino-3,6-galactan-protein (mean Mr 100 000),
which activates macrophages to release tumour necrosis
factor and possess anticomplementary activity and neutral
fucogalactoxyloglucan (mean Mr 22 500), which increases
10-isobutyryloxy-8,9-didehydro-thymol Thymol methyl ether
Figure 8 Thymol derivatives of Arnica montana plant.
Zierone (terpenoid) Dimethyl-ionone Pinchotene acetate Isobornyl 2-methyl butanoate Terpineol
Isobornyl isovalerate p-mentha-2,4-diene 2,6 diisopropyl anisole Isobornyl isobutanoate
Bornyl acetate a-isocomene Modeph-2-ene Trans-a-bergamotene
Silphiperf ol-6-ene Diisopropyl benzene Pyrrolideneacetic acid p-methoxyheptanophenone
Figure 9 Other phytoconstituents of Arnica montana plant.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 933
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
Antimicrobial activity
Arnica montana extracts also exhibit antimicrobial activ-
ity against Streptococcus sobrinus 6715 and Strep.
Mutans OMZ 175. Agar diffusion method was used,
and zones of inhibition were measured. Slight inhibition
was observed of the growing cells (19% for Strep.
mutans OMZ 175 and 15% for Streptococcus sobrinus
6715) and of water-insoluble glucan formation (29%) at
these same concentrations.
These thymol derivatives present in the roots of A. mon-
tana have been reported to have bactericidal and fungicidal
property whereas the essential oil extracted from the roots
of the plant shows antiphlogistic action.
Anti-osteoporotic activity (ossification)
US Pat. No. 5478579 by Sawruk taught that A. montana is
a significant source of flavonol aglycone glycoside which
when combined in specific dose with calcium assists in
absorption of calcium through a chelation delivery
Improves circulation
Arnica montana is reported to relieve symptoms of diseases
relating to the restricted blood flow to nerve endings and
the limbs of patients, and reflex sympathetic dystrophy syn-
drome, which includes fibromyalgia, toxic neuropathy and
diabetic neuropathy.
Ureotonic activity
The alcoholic extracts of A. montana flower heads or
sesquiterpene lactones isolated from the plant show signifi-
cant uterotonic and contraction-enhancing activity in rab-
bits, rats and cats when injected intravenously (0.3 ml of an
Increase respiration
Sesquiterpene lactones, i.e. 6-O-acetyl-11,13-dihydrohele-
nalin present in A. montana, are also reported to increases
respiration frequency and volume by 35 and 43%, respec-
tively, in rats and rabbits when injected intravenously,
0.25 mg/kg bw.
Inotropic activity
Helenalin isolated from A. montana show significant
biphasic positive inotropic effect on the myocardium of
guinea pigs at concentrations of 10
ever, concentrations above 10
mol cause an irreversible
negative inotropic action leading to a block of muscle con-
Internal use of A. montana at a dose of five drops, three
times a day, improves the mild weakness of heart and ang-
ina pectoris.
Anxiolytic activity
Ahmed et al. in 2013 evaluated various neuropharmacolog-
ical screening tests like open field activity, stationary rod
activity test and head dip activity of A. montana.
It was observed that the tannins and flavonoids present
in A. montana extract decrease the exploratory activity and
locomotor activity in mice and mice spent more time
in light compartment and therefore had anxiolytic effect.
The development of immobility during forced
swimming test indicated the cessation of affective/motiva-
tional behaviour.
Antioxidant and protective effect
Arnica montana extract shows significant antioxidant
potential. DPPH (2,20-diphenyl-1-picrylhydrazyl radical)
free radical scavenging method and phosphomolybdate
method have been utilized to determine the antioxidant
potential of the plant. At concentration of 5 mg/ml,
A. montana shows 71.52% DPPH scavenging potential and
63.68% total antioxidant activity (phosphomolybdate
method) which is mainly attributed due to the presence of
flavonoids and phenolic compounds.
Camargo et al. in 2013, evaluated homoeopathic A.
montana’s effect on Ca2
and inorganic phosphate-induced
mitochondrial oxidative stress or/and lipid peroxidation
mediated by Fe2
citrate by alterations rates of oxygen con-
sumed using mitochondrial suspensions prepared by the
livers of Wistar strain male rats. Arnica 30cH showed
remarkable reduction in mitochondrial O
Arnica 30cH provides protection against Ca
and inor-
ganic phosphate-induced hepatic mitochondrial membrane
permeability, lipid peroxidation mediated by Fe
and reactive oxygen-mediated protein fragmentation.
Hepatoprotective activity
Phenolic compounds isolated from A. montana are used to
revive the bile forming function of liver and improve
the release of chelates and bilirubin and the removal of
Marchishin et al. in 1983 have reported that Arnica when
administered to rats with carbon tetrachloride that induced
liver injury increases the synthesis and excretion of bile
acids, bilirubin and cholesterol; bile secretion also acceler-
ates the activity of serum enzymes.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945934
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
Insecticidal activity
Arnica montana furnished insecticidal monoterpenoids
which play significant role against store grain pest Tri-
bolium castaneum. Alcoholic dilutions of extracts of drugs
were prepared in various concentrations, increase the per-
centage mortality when used in concentrations, 1100 mg/
2 ml against store grain pest. In this study, methanol was
used as control and permethrin as standard.
Hypopigmentation activity
Skin withers with age and also by different environmental
stressors such as solar ultraviolet radiation, which leads to
skin damage such as thickening like plaque, deep furrow-
ing, wrinkle formation, erythema, loss of skin tone and also
hyperpigmentation as a result of increased melanin forma-
tion. AM-2 (helenalin 2-methylbutyrate) or A. montana
extract when used to treat cultured mouse melanoma cells
boosts the HSP70 gene expression with increase in dose
and also activates the transcription factor for hsp genes, i.e.
heat shock factor-1. It is concluded that both A. montana
extract and AM-2 can give good results if incorporated in
hypopigmenting cosmetics.
Antihair loss activity
Kennedy et al. in 2012 concluded that A. montana (1.6
2.6% by weight of formulation) in combination with aqua
ammonia in herbal preparations promote hair follicles,
increase hair strength and growth of hair.
Keeney et al. in 2000 introduced a solution containing aloe
vera gel, A. montana flowers, comfrey leaves, jaborandi
leaves, elkweed, chamomile flowers, colloidal silver solu-
tion, horsetail herbal extract, jojoba, collagen, napca, elas-
tin, saponins and rosemary leaves to be applied topically
for boosting growth of hair.
Antiplatelet activity
Pawlaczyk et al. in 2009 found that hexuronic acids and
phenolic glycoconjugates present in A. montana are
responsible for the anticoagulant activity of the plant.
The activity was calculated tests on human plasma such as
prothrombin time and activated partial thromboplastin
time test.
In 1990, Schroder et al. demonstrated that the
sesquiterpene lactones, i.e. helenalin and 11a-13-dihydro-
helenalin, are mainly responsible for the antiplatelet activ-
ity of the plant using human venous blood for test.
Helenalin contains an a-methylene-r-butyrolactone and an
R-unsaturated cyclopentenone moiety which reacts with
intracellular thiol groups leading to their depletion and
inhibiting aggregatory activity and secretory activity in
platelets. Both compounds interact with platelet sulfhydryl
groups causing inhibition of formation of thromboxane,
secretion of 5-hydroxytryptamine and platelet aggregation
induced by collagen at 3300 ukl concentration as a result
of decreased phospholipase A2 activity.
Arnica montana extract is also marked in literature to heal
wounds. In mice, acetic acid-induced writhing test was
used to measure this activity. 0.6% acetic acid per kg was
injected intraperitoneal, and it was concluded that A. mon-
tana, reduces writhes maximally at a dose of 100 mg/kg.
In another study, it is reported that A. montana alone or
in combination with H.perforatum gel heals surgically
induced incision on the back of Wistar rats effectively.
Arnica 6CH pills showed significant potential against oeso-
phageal reflux which is a very productive cough, hiatus her-
nia. Bruises disappeared immediately, and the cough was
gone too.
Antihaemorrhagic activity
Stem tincture of A. montana was found to possess anti-
haemorrhagic activity in women of age group 2035 years,
which reduced postpartum blood loss, which is the signifi-
cant cause of perinatal morbidity and worldwide mortality,
and which occurs in 4% of vaginal deliveries.
Clinical studies
Many clinical studies have been carried out on A. montana.
Data are given in Table 1.
Toxicological studies
The oral LD50 of an extract was >5 g/kg in rats and
123 mg/kg in mice. The LD50 using intraperitoneal
administration was 31 mg/kg for mice. It has been
reported in literature that Arnica preparations does not
show any signs of contact dermatitis (when used topi-
cally), or any ocular irritation, phototoxicity but shows
mutagenic effects due to flavanols present in the plant.
The Arnica extract increased the numbers of revertants
24 times when determined by utilizing S. Typhimurium
TA98 and TA100 in the AMES test. The adverse effects
may occur with a frequency of 1 : 100, and it depends
on the immune system of individual.
Some of the
laboratory findings of side effects of Arnica preparations
are reported in Table 2.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 935
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
Table 1 Clinical Studies of Arnica montana.
Authors (years)
Study design
control type
Duration of
treatment Study and control drugs
Number of subjects by
arms dose; age Diagnosis inclusion criteria Exclusion criteria Efficacy results
Savage et al.
Double-blind, placebo-
3 months 1Arnica 30C, one tablet of medi-
cated lactose after every 2 h
Placebo: Lactose tablets
40 patients (20 men and
20 women) of 77.2
80.5 years
Acute stroke illness Not reported No statistically significant
difference in both groups
Kaziro et al.
Double-blind trial, placebo-
8 days after
removal of
1Metronidazole (400 mg tablets)
2Arnica 200 tablets
3Placebo tablets
118 patients Patients with impacted
mandibular wisdom
Not reported Metronidazole reduced the pain
and enhanced the healing
process after surgery. Arnica
was even less effective than
the placebo
Albertini and
Goldberg et al.
Randomized placebo-
controlled trial
1Arnica 7c and Hypericum 15c
30 patients Dental neuralgic pain after
tooth extraction
76% of the patients treated
with homoeopathic remedies
had pain relief vs 40% of
patients receiving placebo
Dorfman et al.
Double-blind, placebo-
controlled clinical study
1Arnica 5c 39 patients Prolonged venous perfusion Arnica reduced pain,
hyperaemia, oedema and
haematoma formation.
Improvement in the blood
flow and slight increase in
coagulation factors and in
platelet aggregation were
observed after Arnica
Brock et al.
Double-blinded; placebo-
3 weeks 1Combination ointment: (100 g
contain: 10 g extract from Arnica
flowers with sunflower oil (1 + 5)
4000 IU Heparin 5 mg Oil.
Chamomillae 5 mg Guajazulen)
2Mono-ointment: (100 g contains:
10 g extract from Arnica flowers
with sunflower oil (1 + 5))
3Placebo ointment base
159 overall; not reported,
how many per group;
age not reported
Chronic venous
No diuretica Changes were in the
combination treatment, but
differences were not
statistically significant
Lokken et al.
Double-blind, placebo-
controlled crossover trial
1Arnica 30D
24 Pain after surgical removal
of bilaterally impacted
mandibular third molars
No difference in postsurgical
pain was observed between
Arnica and placebo.
Postoperative swelling and
bleeding were not
significantly affected by
Hart et al.
Double-blind placebo-
23 weeks after
1Arnica C30
93 women Patients undergoing
abdominal hysterectomy
Patients with previous
chronic pain or undergo
Arnica in homoeopathy has no
significant effect on
postoperative recovery
Tveiten et al.
Randomized double-blind 5 days (1 day
running and
3 days after
the run
1Arnica D30
24 in group A (27
54 years)
22 in group in group B
(3150 years)
Muscle soreness Not reported Arnica D30 has positive effect
on muscle soreness than
placebo but not on cell
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945936
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
Table 1 (Continued)
Authors (years)
Study design
control type
Duration of
treatment Study and control drugs
Number of subjects by
arms dose; age Diagnosis inclusion criteria Exclusion criteria Efficacy results
Ernst et al.
Computerized literature
searches were
performed to retrieve all
studies on the subject.
The following databases
were searched:
CISCOM, and the
Cochrane Library. 89
studies were included
NA Pure Arnica formulations NA NA Arnica in combination with
other herbs
Homoeopathic arnica is not
efficacious beyond a placebo
Andrew et al.
Double-blind placebo-
controlled trial
2 days after run 1A homoeopathic medicine (Arnica
519 runners Delayed-onset muscles
soreness after long-
distance races
Not reported Homoeopathic Arnica 309is
ineffective for muscle
Baillargean et al.
Double-blind, double-
period, crossover
2 weeks 1Arnica montana 5CH
18 men of 2246 years of
Healthy subjects Patients having any
coagulation disorder,
chronic disease, smoking
or on any other
Arnica montana has no
significant effect on bleeding
time in minutes, and no
clinical significant difference
on other tests of blood
coagulation was observed
Ramelet et al.
Randomized, prospective,
multicentre double-blind
1Arnica 5c
130 Saphenousstripping No significant difference in
postoperative haematomas
was observed between
Arnica and placebo
Brock (2001)
3 weeks 1100 g Arnica gel (contained 25 g
Arnica tincture)
50 per group; 77 woman;
23 men; age in average
Chronic venous
Not reported Statistically significant
improvement in both groups;
a significant better effect in
the verum group
Alonso et al.
Double-blinded placebo-
2 weeks, either in
or post-
1Arnica gel (A. montana with 45%
alcohol, purified water, with hazel,
trolamine, carboner, EDTA,
methyl/propyl paraben)
9 pretreatment, 10 post-
treatment; dose not
specified; age unknown
Facial telangiectases Patients on anticoagulant
No statistically significant
difference in both groups
Rosen-zweig et al.
Double-blinded placebo-
4 weeks 1Arnica compress (prepared from
the whole plant extract, 0.7%)
2Placebo compress (contained
water and food colouring)
16 Arnica 14 placebo;
one compress; age
Acute soft tissue pain (foot/
ankle, knee, neck/
Not reported No statistically significant
analgesic benefit compared
to placebo one hour after
Knuesel et al.
This open multicentre trial Applied twice
daily for
6 weeks
1Arnica montana fresh plant gel 26 men and 53 women Mild-to-moderate
osteoarthritis (OA) of the
Not reported Arnica gel was found to be
effective in treating mild-to-
moderate osteoarthritis
Jeffrey and
Randomized double-blind,
placebo-controlled study
1Arnica 6D tablets
2Arnica Ointment
37 Hand surgery (endoscopic
carpal tunnel release)
No difference in grip strength or
wrist circumference was
found between Arnica and
placebo. A significant
reduction in pain was
observed in the Arnica-
treated group vs placebo. (P
5 0.03)
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 937
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
Table 1 (Continued)
Authors (years)
Study design
control type
Duration of
treatment Study and control drugs
Number of subjects by
arms dose; age Diagnosis inclusion criteria Exclusion criteria Efficacy results
Wolf et al.
Prospective, randomized,
double-blind, placebo-
controlled pilot trial
1Arnica 12D
60 Varicose vein surgery Haematoma surface was
reduced with Arnica by
75.5% and with placebo by
71.5% (not significant). Pain
score decreased by 1, 6, 2.2
points with Arnica and 0.3,
6, 0.8 points with placebo.
The results of the study
showed a trend towards a
beneficial effect of Arnica
regarding the reduction in
haematoma and pain during
the postoperative course
Stevinson et al.
Double-blind, placebo-
controlled, randomized
21 days 1Three tablets daily of homoeo-
pathic Arnica 30 or 6 °C
2Placebo for 7 days before surgery
and 14 days after surgery
64 adults (1870 years) Adults undergoing elective
surgery for carpal tunnel
Patients currently taking
homoeopathic remedies,
reported previous
hypersensitivity to
homoeopathy, were
taking aspirin, or were
unable to complete the
study diary or attend
follow-up appointments
No statistical differences were
found between
homoeopathic arnica over
placebo in reducing
postoperative pain, bruising
and swelling in patients
Totonchi et al.
Double-blinded placebo-
6 days, resp.
4 days
1Intravenous dexamethasone intra-
operatively, followed by a 6-day
dose of prednisone
2Arnica SinEcch
3none (as control)
48 overall; 11 male; 37
female; age from 15 to
Primary rhinoplasty with
Not reported Statistically no significance
between the groups in
ecchymosis; statistically
significance in reducing
oedema in both groups
Oberbaum et al.
Double-blind, placebo-
controlled, randomized,
clinical trial
Before delivery
and 72 h after
1Arnica montana C6 and Bellis
perennis C6
2Arnica montana C30 and Bellis
3Double placebo
Women aged 2035, at
week 3743 of
pregnancy, after one to
four previous deliveries,
and scheduled for
spontaneous vaginal
delivery of a single fetus
Pregnant women Women with previous
Caesarean section,
antepartum or
haemorrhage in previous
pregnancies, and
Homoeopathic Arnica montana
and Bellis perennis may
reduce postpartum blood
loss, as compared with
Leivers (2005)
Double-blind, placebo-
controlled, randomized,
clinical trial
6 weeks 1Arnica gel (20% tincture)
89 patients Venous insufficiency Not reported There was improvement in
venous tone and oedema in
patients on Arnica treatment
than on placebo
Leivers (2005)
Open, multicentre trail 6 weeks 1Arnica gel (20% tincture)
79 patients Mild-to-moderate knee
Not reported Arnica decreased the pain,
stiffness of knee and was
effective than placebo
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945938
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
Table 1 (Continued)
Authors (years)
Study design
control type
Duration of
treatment Study and control drugs
Number of subjects by
arms dose; age Diagnosis inclusion criteria Exclusion criteria Efficacy results
Seeley et al.
Randomized double-blind
placebo-controlled study
1Arnica (SinEcch)
29 patients Rhytidectomy Patients receiving Arnica had a
smaller area of ecchymosis
on postoperative days 1, 5, 7
and 10. These differences
were statistically significant
only on postoperative days 1
(P, 0.005) and 7 (P, 0.001)
Brinkhaus et al.
Three randomised, placebo-
controlled, double-blind,
sequential clinical trials
Patients were
treated and
followed up for
2 (ART), 8
11 days (ARJ)
Homoeopathic Arnica 309(a
homoeopathic dilution of
1 : 1030) administered orally with
sucrose globules as the carrier
A total of 227 patients
were enrolled patients
of both genders, age 18
75 years
Patients with knee diseases
arthroscopy, artificial
knee joint implantations
or cruciate ligament
Recent traumas, acute knee
autoimmune disease,
tumour diseases, alcohol
abuse, serious systemic
mental or physical
disease, severe allergic
disease, pregnancy,
breastfeeding, regular
analgesic consumption,
drug abuse or
participation in another
clinical trial
Patients receiving homoeopathic
arnica showed a less
postoperative swelling mainly
in CLR trails.
Robertson et al.
Randomised double-blind,
2 tablets 6 times
in the first
day and then 2
tablets twice a
day for the
next 7 days.
14 days trail
Arnica 30c or identical placebo 190 patients over the age
of 18
Patients under
Patients who had
tonsillectomy in
combination with other
surgery (e.g.
Arnica montana given after
tonsillectomy provides a
small, but statistically
significant, decrease in pain
scores compared to placebo
Widrig et al.
Double-blind Doses of gel
(4 cm strip),
gently rubbed
over the
affected joints
thrice-daily for
3 weeks
Gel preparations
1Ibuprofen (5%)
2Arnica (50 g tincture/100 g, DER
1 : 20)
204 patients Osteoarthritis of hands Not reported Preparation of arnica is not
inferior to ibuprofen when
treating osteoarthritis of
Totonchi and
Guyuron et al.
Randomized double-blind
clinical study
2Intravenous dexamethasone plus
oral tapering dose of methylpred-
nisone or no treatment (control
48 patients Rhinoplasty Arnica and dexamethasone
reduced swelling oedema if
compared with control (P,
0.0001). Arnica and control
group exhibited more
resolution of ecchymosis if
compared with
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 939
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
Table 1 (Continued)
Authors (years)
Study design
control type
Duration of
treatment Study and control drugs
Number of subjects by
arms dose; age Diagnosis inclusion criteria Exclusion criteria Efficacy results
Paris et al.
A phase 3 monocentric
randomized placebo-
controlled study
1Granule composition containing
Arnica 5c, Bryonia alba 5c, Hyper-
icum perforatum 5c and Ruta
graveolens 3D
2Placebo or no treatment
158 patients Knee ligament
Homoeopathic treatment was
not superior to placebo in
reducing 24-h morphine
consumption after knee
ligament reconstruction.
Nonsignificant difference in
pain assessed by visual
analog scale was observed
between Arnica and placebo
Karow et al.
Randomized double-blind,
parallel-group study
1Arnica 4D
2Diclofenac sodium
88 patients Hallux valgus surgery Arnica and diclofenac had
equivalent efficacy on wound
irritation, patient mobility
and use of analgesics.
Diclofenac was more
effective in reducing pain if
compared with Arnica
Adkison et al.
Randomized, double-blind,
placebo-controlled trial
1Arnica cream
53 patients Leg pain after calf raises Arnica increased pain scores if
compared with placebo. No
difference in muscle
tenderness and ankle motion
was observed
Cornu et al.
Double-blind placebo-
controlled parallel trial
1A combination of Arnica montana
5c and Bryonia alba 5c granules
90 patients Aortic valve surgery No difference between
homoeopathic treatment and
placebo on bleeding, C-
reactive protein, troponin I
and cumulated morphine
was observed
Leu et al.
Randomized, double-blind
placebo-controlled trial
15% vitamin K
21% vitamin K and 0.3% retinol or
35% vitamin K or
420% Arnica or white petrolatum
16 patients 595-nm pulsed-dye laser-
induced bruises on the
bilateral upper inner
The mean improvement in
bruising associated with 20%
Arnica was greater than with
white petrolatum (P5
0.003), and the mixture of
1% vitamin K and 0.3%
retinol (P5 0.01) while
improvement with Arnica
was not greater than with
5% vitamin K cream
Huber et al.
Single-blind, randomized 30 days Combudoron consists of an
ethanolic extract of stinging nettle
(Urtica urens) and Arnica (Arnica
montana). Placebo liquid
consisted of equivalent ethanol
without extract from stinging
nettle and Arnica
Two healthy male subjects
(Caucasian, age 33 and
47 years, body mass
index 24 and 23 kg/m
Erbium YAG-
Laser-induced burns
Not reported Combudoron seems to have
positive effects on healing of
grade 2 laser-induced burns
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945940
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
Table 1 (Continued)
Authors (years)
Study design
control type
Duration of
treatment Study and control drugs
Number of subjects by
arms dose; age Diagnosis inclusion criteria Exclusion criteria Efficacy results
Kucera et al.
Double-blind placebo-
controlled study
10 days 1Combination of Arnica tincture
and HES (spray)
2Arnica or HES or placebo
570 patients Acute ankle joint distortion Patients with fractures or
complete tears of
ligaments, sports
professionals and
pregnant women
On days 34, improvement in
pain on active motion was
significantly higher in the
Arnica +HES group if
compared with the other
three groups
Goedemans et al.
12 months 1Arnica cream
2mucopolysaccharide polysulfuric
40 patients Pain and bruising following
postneedling infiltration
There were no statistical
differences in the effects of
arnica and hirudoid on pain
and bruising
Double-blind, placebo-
4 days 1Arnica montana
28 subjects of 1889 years
of age
Candidates for rhinoplasty
surgery at UW
Patients who are prisoner,
pregnant and
breastfeeding women,
taking anticoagulants
(such as blood thinners),
antiplatelet drugs (such
as NSAIDS), oral
corticosteroid or other
homoeopathic remedies
during the peri-operative
Patients with a bruising
or bleeding disorder,
severe liver or kidney
disease, malignancy,
metabolic syndrome,
infectious or
gastrointestinal disease,
oral or contact allergies
to Arnica montana or to
any other member of
the Asteraceae family
Mariani et al.
Not reported Aqueous extract
of Arnica
planta tota Rh
once a day for
6 days. 15
patients (group
A) received
3 months of
Arnica planta tota Rh D3 30 inpatients (age 5087) Low back pain Patients with other
Patients improved during acute
treatment with no side effect
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 941
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
In this review, the morphology, distribution, pharmacolog-
ical data and phytochemistry of the medicinal plant,
A. montana, have been studied. The pharmacological and
phytochemical studies of the plant have revealed that the
plant possess numerous activities. Although from time
immemorial, the extracts of the plant have been utilized to
treat various ailments but proper investigation of its
mechanism of action, pharmacotherapeutics, toxicity pro-
file, standardization and clinical studies, modern dosage
forms of various phytoconstituents present in the plant can
be prepared. Till date, significant investigations have been
carried out on exploring the medicinal potential of the
flowers of the plant. So, now there is a need to explore the
medicinal potential of other parts of the plant to produce
economic and therapeutically better products.
1. Sahid M, Rao NK. First record of the
two Asteraceae species from the Uni-
ted Arab Emirates. J New Biol Rep
2015; 4: 215218.
2. Kenny O et al. Investigating the
potential of under-utilised plants
from the Asteraceae family as a
source of natural antimicrobial and
antioxidant extracts. Food Chem 2014;
161: 7986.
3. Obon C et al. Arnica: a multivariate
analysis of the botany and ethnophar-
macology of a medicinal plant com-
plex in the Iberian Peninsula and the
Balearic Islands. J Ethanopharmacol
2012; 144: 4456.
5. Magdalena Nikoli C, Stevovi SC.
Family Asteraceae as a sustainable
planning tool in phytoremediation
and its relevance in urban areas.
Urban For Urban Green 2015; 14:
6. Erbar C, Leins P. Diversity of styles
and mechanisms of secondary pollen
Table 2 Laboratory findings of side effects of Arnica montana
Author(s), (year) Formulation Pathology Side effect profile Dose
Hausen et al.
Body lotion containing
extracts of Arnica
Skin lesions Allergic contact dermatitis of the
face and hands
Leeuw et al.
Jogging cream, a
multicombination with
32 constituents, one of
them Arnica
Delmonte et al.
A cream containing 1.5%
Enlarging necrotic lesions
of the face and left
leg, together with
malaise and high fever
Sweet’s Syndrome, often
correlated with leukaemia
Knuesel et al.
Gel (topical application) Knee osteoarthritis One allergic reaction (not
Stevinson et al.
Tablets (oral treatment) Hand surgery (carpal
tunnel syndrome)
Dry mouth
Feeling ‘throbby’ in head/neck
Sore tongue
Arnica 6c (for drowsiness
and sore tongue)
Arnica 30c (for dry
mouth, headache, and
feeling ‘throbby’)
Widrig et al.
Gel (topical application) Hand osteoarthritis Skin irritations
Allergic eczema
Increased finger pain
Karow et al.
Pills (oral treatment) Hallux valgus surgery Abdominal complaints
Racing heart
Arnica 4D
Cornu et al. (2010)
Granules (oral treatment) Aortic valve surgery Cardiovascular events (observed
in both homoeopathy and
placebo groups)
Arnica 5c and Bryonia
alba 5c
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945942
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
presentation in basal Asteraceae new
insights in phylogeny and function.
Flora Morphol, Distrib, Funct Ecol
Plants 2015; 217: 109130.
7. Dietz V. Homeopathic and herbal
preparations of Arnica montana for
treatment of musculoskeletal injuries.
Integrative Medicine 1998; 1: 4244.
8. Maguire B. A monograph of the
genus Arnica (Senecioneae, Composi-
tae). Brittonia 1943; 4: 386510.
9. Aiello N et al. Morpho-quantitative
and qualitative traits of Arnica mon-
tana L. wild accessions of Trentino,
Italy. Ind Crops Prod 2012; 40: 199
10. Assessment report on Arnica montana
L., flos, European Medicines Agency
(Science medicines agency), EMA/
HMPC/198794/2012: 125.
11. Schroder H et al. Helenalin and
11a,13-dihydrohelenalin, two con-
stituents from Arnica montana L.,
inhibit human platelet function via
thiol-dependent pathway. Thromb Res
1990; 57: 839845.
12. Clair S. Arnica: a proven first aid rem-
edy for injuries and accidents. J N Zeal
Assoc Med Herb 2010; 1213.
13. European Pharmacopoeia, 3rd edn,
TSO (August 2000): Council of Eur-
ope, 2000: 396398.
14. Archer HK, Pettit MS. Analgesic and
antiphlogistic compositions and thera-
peutic wrap for topical delivery. 1997
Patent No.US 5976547 A.
15. Alam M. Topical Arnica treatment for
reducing bruising. 2009 Patent No.
US 20090104292 A1.
16. Marissal J, Aubert LP. Slenderizing
and anti-cellulitis cosmetic composi-
tion based on an extract of a plant
containing saponins, an extract of
Arnica montana L. and a kola nut
extract, and to a process for using the
same. 1987 Patent No. US 4684522 A.
17. Zelaya LM. Oral rinse composition.
1994 Patent No. US 5376374 A.
18. Paradise L. Homeopathic pharmaceu-
tical compositions, US 5795573A
19. Dreyer LR. Homeopathic formulations
useful for treating pain and/or inflam-
mation. Patent No. 7923040.
20. Bilia AR et al. Development and sta-
bility of semisolid preparations based
on a supercritical CO
Arnica extract.
J Pharm Biomed Anal 2006; 41: 449
21. Committee for Veterinary Medicinal
Products-Arnica montana. European
agency for the evaluation of medicinal
products, veterinary medicinal evalua-
tion unit, 1999.
22. Aeschbach R et al. Antioxidant actions
of thymol, carvacrol, 6-gingerol, zin-
gerone and hydroxytyrosol. Food
Chem Toxicol 1994; 32: 3136.
23. Petrova M et al. Biotechnological
approaches for cultivation and
enhancement of secondary metabolites
in Arnica montana L.Acta Physiol
Plant 2012; 123133.
24. Wagner H. Birkhauser Verlag
Immunomodulatory agents from
plants, 1999.
25. Ismail R. Agents for the treatment
and protection of the skin 1990,
Patent No. US 4938960 A.
26. Ganzera M et al. Quantitative analysis
of flavonoids and phenolic acids in
Arnica montana L. by micellar elec-
trokinetic capillary chromatography.
Anal Chim Acta 2008; 614: 196200.
27. Paßreiter CM. Co-occurrence of 2-
pyrrolidineacetic acid with the
pyrrolizidines tussilaginic acid and
isotussilaginic acid and their 1-epi-
mers in Arnica species and Tussilago
farfara.Phytochemistry 1992; 131:
28. Staneva J et al. Quantitative analysis
of sesquiterpene lactones in extract of
Arnica montana L. by
H NMR spec-
troscopy. J Pharm Biomed Anal 2011;
54: 9499.
29. Spitaler R et al. Altitudinal variation
of secondary metabolite profiles in
flowering heads of Arnica montana cv.
ARBO. Phytochemistry (Amsterdam)
2006; 67: 409417.
30. Spitaler R et al. Altitudinal variation
of phenolic contents in flowering
heads of Arnica montana cv. J Chem
Ecol 2008; 34: 369375.
31. Wagner S, Merfort I. Skin penetration
behaviour of sesquiterpene lactones
from different Arnica preparations
using a validated GC-MSD method. J
Pharm Biomed Anal 2007; 43: 3238.
32. Douglas JA et al. Sesquiterpene lac-
tones in Arnica montana: a rapid ana-
lytical method and the effects of
flower maturity and simulated
mechanical harvesting on quality and
yield. Planta Med 2004; 70: 166170.
33. Leven W, Willuhn G. Spectrophoto-
metric determination of sesquiter-
penelactone S1 in Arnicae Flos Dab 9
with m-dinitro-benzene. Planta Med
1986; 52: 537538.
34. Merfort I. Caffeoylquinic acids from
flowers of Arnica montana and Arnica
chamissonis.Phytochemistry 1992; 31:
35. Dziki UG et al. Seeds of Arnica mon-
tana and Arnica chamissonis as a
potential source of natural antioxi-
dants. Herba Polonica 2009; 55: 6071.
36. Aiello N et al. Seed yield and germi-
nation characteristics of wild acces-
sions of Arnica montana L. from
Trentino (Italy). J Appl Res Med Aro-
mat Plants 2014; 1: 3033.
37. Pljevljakusic D et al. Rhizome and
root yield of the cultivated Arnica
montana L., chemical composition and
histochemical localization of essential
oil. Ind Crops Prod 2012; 39: 177189.
38. Kennedy JF et al. Analysis of the
oligosaccharides from the roots of
Arnica montana L., Artemisia
absinthium L., and Artemisia dracuncula
L.Carbohyd Polym 1998; 9: 277285.
39. Weremczuk-Je_
zyna I et al. Constituents
of the essential oil from hairy roots
and plant roots of Arnica montana L. J
Essent Oil Res 2011; 23: 9197.
40. Huber R et al. Arnica and stinging
nettle for treating burns a self-
experiment. Complement Therap Med
2011; 19: 276280.
41. Lyss G, Schmidt TJ, Merfort I, Pahl
HL. Helenalin, an anti-inflammatory
sesquiterpene lactone from Arnica,
selectively inhibits transcription factor
NF-kappaB. Biol Chem 1997; 378:
42. Bellavite P, Ortolani R, Conforti A.
Immunology and Homeopathy. 3. Exper-
imental Studies on Animal Models. Evid
Based Complement Alternat Med 2006; 3:
43. Kawakami AP et al. Inflammatory
process modulation by homeopathic
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 943
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
Arnica montana 6CH: the role of indi-
vidual variation. Evid Based Comple-
ment Alternat Med 2011; 2011:
44. Widrig R et al. Choosing between
NSAID and Arnica for topical treat-
ment of hand osteoarthritis in a ran-
domised, double-blind study.
Rheumatol Int 2007; 27: 585591.
45. Puhlmann J et al. Immunologically
active polysaccharides of Arnica mon-
tana cell cultures. Phytochemistry
1991; 30: 11411145.
46. Koo H et al. In vitro antimicrobial
activity of propolis and Arnica mon-
tana against oral pathogens. Arch Oral
Biol 2000; 45: 141148.
47. Sawruk S. Method for treatment of
osteoporosis. 1995 U.S. Patent No.
No. 5,478,579.
48. Savage RH, Roe PF. A further double
blind trial to assess the benefit of
Arnica montana in acute stroke illness.
Br Homeopath J 1978; 67: 210222.
49. Valan MF, Brittob JB, Venkataramanc
R. Phytoconstituents with hepatopro-
tective Activity Int. J Chem Sci 2010;
8: 14211432.
50. Ahmad M et al. Neuro-pharmacologi-
cal and analgesic effects of Arnica
montana extract. Int J Pharm Pharm
Sci 2013; 5: 590593.
51. Keeney JA. Compositions for stimu-
lating hair growth, preventing hair
loss, or minimizing hair loss, and
methods for preparing and using
same. 2000 Patent No. US 6103272 A.
52. Camargo RA et al. Effect of the oral
administration homeopathic Arnica
montana on mitochondrial oxidative
stress. Homeopathy 2013; 102: 4953.
53. Marchishin SM. Efficacy of the phenol
compounds of Arnica in toxic lesion
of the liver. Farmakol Toksikol 1983;
46: 102106.
54. Usui K et al. Identification of HSP70-
inducing activity in Arnica montana
extract and purification and character-
ization of HSP70-inducers. J Dermatol
Sci 2015; 78: 6775.
55. Kennedy E.A. Compositions for stim-
ulating hair growth and preventing
hair loss. 2012 Patent No. US
20140079815 A1.
56. Pawlaczyk I et al. Polyphenolicpolysac-
charide compounds from selected
medicinal plants of Asteraceae and
Rosaceae families: chemical characteri-
zation and blood anticoagulant
activity. Carbohyd Polym 2009; 77:
57. Castro FCB et al. Effects of microcur-
rent application alone or in combina-
tion with topical Hypericum
perforatum L. and Arnica montana L.
on surgically induced wound healing
in Wistar rats. Homeopathy 2012; 101:
58. Ernst E. The benefits of Arnica: 16
case reports. Homeopathy 2003; 92:
59. Oberbaum M et al. The effect of the
homeopathic remedies Arnica mon-
tana and Bellis perennis on mild post-
partum bleeding a randomized,
double-blind, placebo-controlled study
preliminary results. Complement
Ther Med 2005; 13: 8790.
60. Duke JA. Handbook of Medicinal
Plants, 2nd edn., 2002, pubished by
CRC press: 37.
61. Woerdenbag HJ et al. Decreased hele-
nalin-induced cytotoxicity by flavo-
noids from Arnica as studied in a
human lung carcinoma cell line. Phy-
tomedicine 1995; 2: 127132.
62. Kaziro GSN. Metronidazole (flagyl)
and Arnica montana in the prevention
of post-surgical complications, a com-
parative placebo controlled clinical
trial. Br J Oral Maxillofac Surg 1984;
22: 4249.
63. Albertini H, Goldberg W. Evaluation
d’un traitement homeopathique de le
nevralgie dentaire. Bilan de 60
Observa-Tions Dentaires in Recherches
en Homeopathie. Homeopathy 1986; 3:
64. Dorfman P et al.
Evaluation de l’ac-
tivite de l’Arnica 5CH sur les troubles
veineux apr
es perfusion prolongee.
Cahiers de Biotherapie 1988; 98: 77
65. Lokken P et al. Effect of homoeopathy
on pain and other events after acute
trauma: placebo controlled trial with
bilateral oral surgery. BMJ 1995; 310:
66. Hart O et al. Double-blind, placebo-
controlled, randomized clinical trial of
homeopathic Arnica C30 for pain and
infection after total abdominal hys-
terectomy. J R Soc Med 1997; 90: 73
67. Tveiten D, Bruset S. Effect of Arnica
D30 in marathon runners. Pooled
results from two double-blind placebo
controlled studies. Homeopathy 2003;
92: 187189.
68. Andrew V et al. Homeopathic Arnica
30 9 is ineffective for muscle soreness
after long-distance running: a ran-
domized, double-blind, placebocon-
trolled trial. Clin J Pain 1998; 14:
69. Baillargean L et al. The effects of
Arnica montana on bleeding time. A
randomized clinical trial. Biomedical
Therapy 1998; 16: 272276.
70. Ramelet AA et al. Homeopathic
Arnica in postoperative haematomas:
a double-blind study. Dermatology
2000; 201: 347348.
71. Alonso D et al. Effects of topical Arnica
gel on post-laser treatment bruises.
Dermatol Surg 2002; 28: 686688.
72. Knuesel O et al. Arnica montana gel
in osteoarthritis of the knee: an open,
multicenter clinical trial. Adv Ther
2002; 19: 209218.
73. Jeffrey SL, Belcher HJ. Use of Arnica
to relieve pain after carpal-tunnel
release surgery. Altern Ther Health
Med 2002; 8: 6668.
74. Wolf M et al. Efficacy of Arnica in
varicose vein surgery: results of a ran-
domized, double-blind, placebo-con-
trolled pilot study. Forsch Kom-
Plementarmed Klass Naturheilkd 2003;
10: 242247.
75. Stevinson C et al. Homeopathic
Arnica for prevention of pain and
bruising: randomized placebo-con-
trolled trial in hand surgery. J R Soc
Med 2003; 96: 6065.
76. Leivers K. Unravelling the confusion
around Arnica’s herbal and homeo-
pathic use. Pharm J 2005; 275: 289291.
77. Seeley BM et al. Effect of homeo-
pathic Arnica montana on bruising in
face-lifts: results of a randomized,
double-blind, placebo-controlled clinical
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945944
Arnica montana L. a plant of healing: review Priyanka Kriplani et al.
trial. Arch Facial Plast Surg 2006; 8:
78. Brinkhaus B et al. Homeopathic Arnica
therapy in patients receiving knee sur-
gery: results of three randomised dou-
ble-blind trials. Complement Therap
Med 2006; 14: 237246.
79. Robertson A et al. Homeo-pathic
Arnica montana for post-tonsillectomy
analgesia: a randomised placebo control
trial. Homeopathy 2007; 96: 1721.
80. Totonchi A, Guyuron B. A random-
ized, controlled comparison between
Arnica and steroids in the manage-
ment of postrhinoplasty ecchymosis
and edema. Plast Reconstr Surg 2007;
120: 271274.
81. Paris A et al. Effect of homeopathy on
analgesic intake following knee ligament
reconstruction: a phase III monocentre
randomized placebo controlled study.
Br J Clin Pharmaco 2008; 65: 180187.
82. Karow JH et al. Efficacy of Arnica
montana D4 for healing of wounds
after Hallux valgus surgery compared
to diclofenac. J Altern Complement
Med 2008; 14: 1725.
83. Adkison JD et al. The effect of topical
Arnica on muscle pain. Ann Pharma-
cother 2010; 44: 15791584.
84. Cornu C et al. No effect of a homoeo-
pathic combination of Arnica mon-
tana and Bryonia alba on bleeding,
inflammation, and ischaemia after
aortic valve surgery. Br J Clin Pharma-
col 2010; 69: 136142.
85. Leu S et al. Accelerated resolution of
laser-induced bruising with topical
20% Arnica: a rater-blinded random-
ized controlled trial. Br J Dermatol
2010; 163: 557563.
86. Kucera M et al. Arnica/Hydroxyethyl
salicylate combination spray for ankle
distortion: a four-arm randomised
double-blind study. Pain Res Treat
2011; 2011: 365625.
87. Goedemans A et al. Topical Arnica
and mucopolysaccharide polysulfate
(Hirudoid) to decrease bruising and
pain associated with haemodialysis
cannulation related infiltration: a pilot
study. Renal Soc Australas J 2014; 10:
88. Clinical A service of the
U.S. National Institutes of Health.
The Utility of Peri-operative Arnica
montana for Reduction of Ecchymosis
in Rhinoplasty Surgery. 2016.
89. Mariania E et al. Anthroposophical
injectable Arnica montana extract in
acute low back pain: a prospective study.
Eur J Integr Med 2009; 1: 223260.
90. Lannitti T et al. Effectiveness and
safety of Arnica montana in post-sur-
gical setting, pain and inflammation.
Am J Ther 2014; 23: 117.
©2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology,69 (2017), pp. 925–945 945
Priyanka Kriplani et al. Arnica montana L. a plant of healing: review
... Given their capability to modulate inflammation pathways induced by oxidative stress, SL emerge as promising candidates for addressing chronic inflammatory diseases (4,11,15). Notably, helenalin, a pseudoguaianolide sesquiterpene lactone derived from Arnica Montana and Arnica chamissonis ssp. foliosa, has recently regained attention as a lead compound for inflammation treatment (15)(16)(17)(18)(19). Its anti-inflammatory mechanism diverges from that of non-steroidal antiinflammatory drugs (NSAIDs), attributed mainly to its potent inhibition of nuclear transcriptional factor-ß (NF-ß) signaling (6,16). ...
... Notably, helenalin, a pseudoguaianolide sesquiterpene lactone derived from Arnica Montana and Arnica chamissonis ssp. foliosa, has recently regained attention as a lead compound for inflammation treatment (15)(16)(17)(18)(19). Its anti-inflammatory mechanism diverges from that of non-steroidal antiinflammatory drugs (NSAIDs), attributed mainly to its potent inhibition of nuclear transcriptional factor-ß (NF-ß) signaling (6,16). ...
... | NOT PEER-REVIEWED | Posted: 18 September 2023 doi:10.20944/preprints202309.1155.v1 15 The helenalin-based formulation derived from Arnica montana and sodium hyaluronate has demonstrated excellent tolerability and a good safety profile as a lubricant eye drop in individuals with healthy eyes. Additionally, it exhibits notable clinical efficacy by alleviating dry eye-related symptoms (as indicated by the OSDI score), enhancing tear film stability (measured by NIF-BUT, NIAvg-BUT, OSS, Schirmer's test, and meibomiography), and exerting an anti-inflammatory effect (evidenced by the reduction in MMP-9 positivity rate and the normalization of CIC) in patients afflicted with mild to moderate DED. ...
Full-text available
Purpose: To assess the tolerability, safety, and efficacy of an ophthalmic topical formulation containing helenalin from Arnica montana and hyaluronic acid 0.4% (HA) in patients with mild to moderate dry eye disease (DED) exhibiting positive Matrix Metalloproteinase 9 (MMP-9) test results. Methods: Tolerability and safety were evaluated in 24 healthy subjects. Participants were in-structed to routinely apply one drop of the formulation three times a day in the study eye, for a period of two weeks, followed by a clinical follow-up of 21 days. Efficacy was studied in 48 DED patients randomized into Study (Group 1/ receiving the study formulation) or Control (Group 2/ Receiving HA 0.4% eye lubricant) groups, for 4 weeks. Assessments included MMP-9 positivity, conjunctival impression cytology (CIC), Ocular Surface Disease Index (OSDI), non-invasive tear film breakup time (NIF-BUT), non-invasive average breakup time (NIAvg-BUT), ocular surface staining, Schirmer's test, and meibomiography. A crossover design with a four-week follow-up was applied to the control group. Results: Healthy subjects receiving the study formulation exhibited good tolerability and no ad-verse events. Group 1 showed significant MMP-9 reduction (25% positivity rate) unlike Group 2 (87.5% positivity rate). Group 1 displayed improved CIC (33.3% vs. 0% SSD) compared to Group 2 (29.1%). OSDI and NIF-BUT scores improved in both groups (p < 0.001). Only Group 1 showed improved NIAvg-BUT and Schirmer’s test scores (p < 0.001), while Group 2 did not (p > 0.05). MMP-9-positive subjects shifted from 25% to 91.6% in Group 1 and 87.5% to 20.8% in Group 2 after the follow-up. Conclusion: The topical formulation containing helenalin from Arnica montana and hyaluronic acid is well tolerated and has a good safety profile. Our formulation reduces DED sympto-matology and modulates the ocular surface inflammatory process; this is evidenced by the en-hancement of CIC, the improvement of DED-related tear film status, and the reduction of MMP-9 positivity rate.
... En el estudio Arnica montana L. A plant of healing: Review se ha informado que los extractos de plantas poseen actividad antibacteriana, antitumoral, antioxidante, antiinflamatoria, antifúngica e inmunomoduladora. Una amplia gama de compuestos químicos que incluyen lactonas sesquiterpénicas y sus ésteres de ácido carbónico de cadena corta, flavonoides, carotenoides, aceites esenciales, diterpenos, arnidiol, alcaloides de pirrolizidina, cumarinas, ácidos fenólicos, lignanos y oligosacáridos, etc., se encuentran en diferentes partes de la planta [26]. ...
... 150 sustancias terapéuticamente activas están presentes en la planta A. montana, esta tiene lactonas sesquiterpénicas como helenalina, 11a, 13-dihidrohelenalina y sus ésteres de ácido carbónico de cadena corta (0,3-1% del peso seco en las flores, 0,1-0,5% en hojas, también se han visto flavonoides (0,6-1,7%) por cromatografía capilar electrocinética micelar en forma de glucósidos flavonoides, glucurónidos flavonoides y flavonoides agliconas, además de aceites esenciales, compuestos completamente de grasas, ácidos, derivados de timol, monoterpenos y sesquiterpenos [26]. A. montana tiene un potencial antiinflamatorio significativo. ...
... El mecanismo molecular de lactonas sesquiterpénicas difiere del mecanismo de los AINEs. Estas lactonas disminuyen significativamente la inflamación mediada por NF kappa beta a medida que atraviesan la piel [26]. ...
Full-text available
Objetivo: realizar una revisión bibliográfica sobre la fisiología ano-rectal, el proceso de relajación y contracción del músculo liso del tracto digestivo y posibles materias primas y formulaciones que podrían incorporarse a formulaciones erocosméticas de uso tópico en la región ano-rectal. Métodos: la revisión bibliográfica se realizó utilizando diferentes descriptores y mediante la consulta en las bases de datos ScienceDirect, PubMed, Clinical Key, Google Scholar y Google Patents. Resultados: inicialmente la revisión de la literatura permite comprender la anatomía y fisiología ano-rectal y los mecanismos que modulan la continencia anal, el tono basal del esfínter anal interno y el reflejo inhibitorio rectoanal (RAIR). Posteriormente, se obtuvo información sobre ejemplos de afrodisíacos naturales y se analizaron formulaciones cosméticas utilizadas como lubricantes anales con el fin de estudiar a profundidad los ingredientes de origen natural e identificar su utilidad, mecanismos de acción tópicos y su función dentro de la formulación. Conclusiones: el entendimiento de la fisiología ano-rectal permite el estudio y desarrollo de formulaciones cosméticas con propiedades analgésicas, anestésicas y relajantes, como los lubricantes anales. Productos naturales como la manzanilla, árnica, Aloe vera y mentol han sido estudiados para su uso cosmético y tópico como analgésicos, anestésicos o relajantes, por lo que su utilidad comprobada los hace útiles en el desarrollo de productos erocosméticos destinados para ser utilizados en la región anogenital.
... while roots contain high levels of thymol, known for its antioxidant, antimicrobial and anti-inflammatory properties [1,7,[10][11][12][13][14][15]. ...
... The anti-inflammatory activity of Arnicae flos, notably its ability to inhibit NF-κB signaling and its downstream 5-lipoxygenase (5-LO)-and cyclooxygenase-2 (COX-2)-mediated pathways, is well documented [1,2,8,9,16]. NF-κB is an important mediator of immune response and inflammation [17]. It regulates the transcription of proinflammatory genes such as arachidonate 5-lipoxygenase (ALOX5) and prostaglandin-endoperoxide synthase 2 (PTGS2). ...
... Both leukotrienes and prostaglandins are directly involved in the processes leading to the early signs of inflammation, including redness, swelling (oedema) and pain [16,[18][19][20][21][22][23][24]. While most studies have investigated the anti-inflammatory activities of Arnicae flos, very little is known of the anti-inflammatory properties of Arnicae planta tota [1,25,26]. We hypothesized that, due to an increased and broader content of bioactive substances, Arnicae planta tota extracts might exert greater anti-inflammatory activities than Arnicae flos extracts. ...
Full-text available
Arnica montana is well known for its anti-inflammatory properties. While the anti-inflammatory activity of Arnica flowers (Arnicae flos) has been extensively studied, that of the whole plant (Arnicae planta tota) is less characterized. We compared the ability of Arnicae planta tota and Arnicae flos extracts to inhibit the pro-inflammatory NF-κB—eicosanoid pathway, using several in vitro and in vivo assays. We showed that Arnicae planta tota inhibited NF-κB reporter activation, with an IC50 of 15.4 μg/mL (vs. 52.5 μg/mL for Arnicae flos). Arnicae planta tota also inhibited LPS-induced expression of ALOX5 and PTGS2 genes in human differentiated macrophages. ALOX5 and PTGS2 encode the 5-lipoxygenase (5-LO) and cyclooxygenase-2 (COX-2) enzymes that initialize the conversion of arachidonic acid into leukotrienes and prostaglandins, respectively. Arnicae planta tota inhibited 5-LO and COX-2 enzymatic activity in vitro and in human primary peripheral blood cells, with lower IC50 compared to Arnicae flos. Finally, Arnicae planta tota applied topically reduced carrageenan-induced mouse paw oedema more efficiently than Arnicae flos. Altogether, Arnicae planta tota displayed a superior anti-inflammatory activity compared to Arnicae flos, suggesting that Arnicae-planta-tota-containing products might be more effective in alleviating the manifestations of acute inflammation than those based on Arnicae flos alone.
... A. montana is characterized by about 1-2 feet tall, perennial, herbaceous, with cauline leaves, hairy stems, and yellow daisy-like flowers. Flowers appear from July to August with 1 to 7 flower heads (Kriplani et al. 2017). The flower teeth are 1-2 mm long and have a radius. ...
... The flowers present a complex mixture of sesquiterpene lactones (STLs) consisting mainly of helenalin esters and 11a,13dihydrohelenaline, which are commonly considered responsible for their therapeutic effects. It is believed that helenaline and its acetate ester have anti-inflammatory activities and were previously shown to inhibit the transcription factor NF-jB, a key regulator of inflammation (Kriplani et al. 2017;Flórez-Fernández et al. 2021;Robledo et al. 2022). ...
Full-text available
Brazilian arnicas belong to the Asteraceae family and can be mainly found in the Brazilian biome Cerrado (savanna) but also Caatinga, Atlantic Forest, Pampa, Pantanal, and Amazonia Forest. The plant’s leaves, roots, inflorescences, and flowers have demonstrated high medicinal potential use as evidenced by recent studies. The Brazilian arnica species were selected based on their ethnopharmacological representativeness, with the 9 most relevant species being identified: Calea uniflora Less, Chaptalia nutans (L.) Polák., Lychnophora ericoides Mart, L. pinaster Mart. and L. salicifolia Mart, Porophyllum ruderale (Jacq.) Cass., Pseudobrickellia brasiliensis (Spreng.) R.M. King & H. Rob. Solidago chilensis Meyen, Sphagneticola trilobata (L.) Pruski. Brazilian arnicas species have many pharmacological/bioactive constituents such as flavonoids, phenolic compounds, and terpenoids, especially monoterpenes, and sesquiterpenes. Experimental in vitro and in vivo studies indicate its benefits to prevent, improve and treat human conditions or diseases with several beneficial effects such as anti-inflammatory, analgesic, antiedematogenic, antimicrobial, antioxidant, trypanocidal, and leishmanicidal activity. Arnicas extracts and their bioactive compounds have been suggested as useful tools in the industry, for example, in topical formulations and green chemistry. Like many other native plants spread throughout Brazil, arnicas have a high functional potential that needs further exploration. In this context, the present review aims to describe the potential use of Brazilian arnicas, highlighting their geographic distribution, uses in traditional medicine, bioactive composition, health effects, and potential applications. Graphical abstract
... * It is mainly a high altitude plant mostly found in mountain areas in Europe, from the Iberian Peninsula to Ukraine, but can also grow in the lowlands. 6 A division of Arnica in two subspecies, i.e., subsp. atlantica representing the southwestern type found on the Iberian peninsula and subsp. ...
... For identification purposes, the most important chemical compounds in A. montana are the following: helenalin, dihydrohelenalin and their corresponding esters (0.3-1% of flower heads dry weight); flavonoids in the form of aglycones, glycosides and glucuronides (0.6-1.7%); essential oil composed of thymol derivatives, monoterpenes, and sesquiterpenes. 6 Helenalin and 11a,13-dihydrohelenalin derivatives in A. montana are presented mostly as acetyl, tigloyl, methacryloyl, isovaleryl, isobutyryl, and methylbutyryl esters of their corresponding sesquiterpene lactones. Two distinct chemotypes exist which have been associated with the two subspecies: subsp. ...
Full-text available
Arnica montana flower extract is a popular ingredient for production of ointments, gels, and homeopathic preparations. Due to nomenclatural confusion, particularly the use of the vernacular name arnica for a number of plant species, difficulties in cultivation, and high prices for wild-harvested plant material, adulteration is quite common. Some of the known adulterants for A. montana flowers are other Arnica species (A. angustifolia, A. chamissonis, A. chamissonis subsp. foliosa), “Mexican arnica” (Heterotheca spp.), and different species from the Asteraceae family (Gaillardia spp., Grindelia spp., etc). This Laboratory Guidance Document (LGD) presents a review of various analytical methods used to differentiate between A. montana flowers, and products containing plant material from other Arnica species or adulterating materials.
... A. montana has been used in traditional and homeopathic medicine for centuries in Europe and North America (Klaas et al., 2002). The anti-inflammatory properties of A. montana may be due to the presence of polyphenolic compounds such sesquiterpene lactones (helenalin, 11α,13-dihydrohelenalin) and flavonoids (Kriplani et al., 2017(Kriplani et al., , 2020. A. montana has been used to alleviate inflammation, pain and swelling associated with trauma, and post-operative clinical conditions (Chaiet and Marcus, 2016;Leu et al., 2010;Smith et al., 2021;Widrig et al., 2007). A. montana is also used as a homeopathic remedy and is available as a topical ointment or as an oral formulation. ...
Ethnopharmacological relevance: The plant Arnica montana L. has been shown to alleviate inflammation, pain and swelling associated with trauma, and post-operative clinical conditions, yet the mechanism of action is not well understood. Aim of the study: The study was designed to investigate the effect of Arnica montana (A. montana) mother tincture and homeopathic dilutions on inflammation markers, oxidative stress and cell migration in diverse cell culture models. Materials and methods: We tested A. montana mother tincture and a range of homeopathic dilutions in different human and murine cell culture models to demonstrate their anti-inflammatory properties by measuring the inflammatory markers: tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), cyclooxygenase-2 (COX-2), monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule (ICAM-1) reactive oxygen species (ROS) and cell migration. The inflammatory markers were measured by ELISA assays. The intracellular oxidative stress (ROS) in microglial cells was measured using Deep Red CellROX probe. The cell migration was examined by wound healing using the Oris Cell migration assay. Results: These data showed the ability of A. montana (mother tincture and mainly 1C dilution) to significantly reduce TNFα production in inflamed macrophages compared with vehicle (control). They significantly reduced both IL-6 and MCP-1 in inflamed human microglial cells and significantly decreased COX-2 expression in inflamed murine fibroblasts. Moreover, A. montana mother tincture reduced the cell migration whereas 9C dilution significantly enhanced the migration of fibroblast cells compared with vehicle. The expression of ICAM-1 was significantly reduced with A. montana mother tincture and 1C, 3C, 5C, and 9C dilutions in inflamed human endothelial cells compared with vehicle. A. montana mother tincture and 1C, 3C, 5C and 9C dilutions induced a significant and consistent effect on ROS production in inflamed murine microglial cells. A. montana 1C had the largest impact on ROS production. Conclusions: Mother tincture and 1C dilution of A. montana showed anti-inflammatory properties assessed by measurement of several markers (pro-inflammatory cytokines, adhesion molecule, ROS) in various human and murine cell models. In addition, A. montana 3C, 5C, 9C dilutions have anti-inflammatory and antioxidant effects as highlighted on both primary endothelial cells and murine microglial cells.
... Arnica montana flowers contain terpenoids, including sesquiterpene lactones, diterpenes, triterpenes (arnidiol, faradiol), flavonoids, essential oils, phenolic acids (caffeic and chlorogenic, and their depsides), coumarins, tannins, saponins and phytosterols [2,3]. ...
Full-text available
Arnica montana is a valuable plant with high demand on the pharmaceutical and cosmetic market due to the presence of helenalin (H) and 11α, 13-dihydrohelenalin (DH) sesquiterpene lactones (SLs), with many applications and anti-inflammatory, anti-tumor, analgesic and other properties. Despite the great importance of these compounds for the protection of the plant and their medicinal value, the content of these lactones and the profile of the compounds present within individual elements of florets and flower heads have not been studied so far, and attempts to localize these compounds in flower tissues have also not been conducted. The three studied Arnica taxa synthesize SLs only in the aerial parts of plants, and the highest content of these substances was found in A. montana cv. Arbo; it was lower in wild species, and a very small amount of H was produced by A. chamissonis. Analysis of dissected fragments of whole inflorescences revealed a specific distribution pattern of these compounds. The lactones content in single florets increased from the top of the corolla to the ovary, with the pappus calyx being a significant source of their production. Histochemical tests for terpenes and methylene ketones indicated the colocalization of lactones with inulin vacuoles.
... Foi relatado que os extratos vegetais possuem atividade antibacteriana, antitumoral, antioxidante, anti-inflamatória, antifúngica e imunomodulatória. Segundo a farmacopeia brasileira de fitoterápicos, ela pode ser usada em preparação extemporânea, tintura, gel e pomadas 19,20 . ...
Full-text available
Introdução: As arboviroses transmitidas pelo gênero Aedes aegypti são um dos principais problemas de saúde pública na atualidade, sendo um deles o vírus Chikungunya, que está se apresentando como parcela crescente desse problema. Desse modo, olhar para outras opções de tratamento aumentam a viabilidade da melhora da qualidade de vida dos acometidos por esse vírus. Objetivos: Identificar estudos publicados nas bases científicas atuais que corroborem os benefícios das práticas integrativas e complementares nos cuidados da sintomatologia advinda da fase crônica da febre chikungunya. Métodos: Revisão integrativa seguindo a metodologia do Joanna Briggs Institute, realizada nas bases de dados de ciências da saúde Scielo, Google Acadêmico, Pubmed, Elsevier, ScienceDirect, Lilacs e Scopus. Foram utilizadas palavras-chave “chikungunya”, “método BioFAO”, “acupuntura”, “gengibre”, dentre outras, nos idiomas português, espanhol e inglês, e considerados os materiais publicados entre os anos 2015 e 2022. Resultados: Foram observados que os tratamentos abordados na presente revisão apresentam evidências de benefícios em prol do bem-estar e melhoria da sintomatologia da fase crônica do vírus Chikungunya. Conclusão: É possível determinar que a indicação e a prescrição de tratamentos complementares, como acupuntura, plantas medicinais e homeopatia BioFAO, podem, sim, ser benéficas no auxílio do controle dos sintomas da chikungunya em sua fase crônica, bem como podem promover melhoria da qualidade de vida dos pacientes acometidos com as dores crônicas da febre Chikungunya.
Full-text available
Background: This project originated from the study of an 18th century manuscript found in Valle Imagna (Bergamo, Italy) which contains 200 plant-based medicinal remedies. A first comparison with published books concerning 20th century folk medicine in the Valley led to the designing of an ethnobotanical investigation, aimed at making a thorough comparison between past and current phytotherapy knowledge in this territory. Methods: The field investigation was conducted through semi-structured interviews. All data collected was entered in a database and subsequently processed. A diachronic comparison between the field results, the manuscript, and a 20th century book was then performed. Results: A total of 109 interviews were conducted and the use of 103 medicinal plants, belonging to 46 families, was noted. A decrease in number of plant taxa and uses was observed over time, with only 42 taxa and 34 uses reported in the manuscript being currently known by the people of the valley. A thorough comparison with the remedies in the manuscript highlighted similar recipes for 12 species. Specifically, the use of agrimony in Valle Imagna for the treatment of deep wounds calls back to an ancient remedy against leg ulcers based on this species. Conclusions: The preliminary results of this study allow us to outline the partial passage through time fragments of ancient plant-based remedies once used in the investigated area.
Full-text available
Similia Similibus Curantur is also called the law of similars. That is, when a drug produces pathological/pathogenic symptoms in healthy individual means, the same drug can relieve similar kinds of symptoms in individuals with the disease. The biological, pharmacological and toxicological action of capsaicin alkaloids is a perfect example to explain the Similia Similibus Curantur principle. Most of the drugs in homoeopathic materia medica contain toxicological, pharmacological, drug-proving, and traditional use-related symptoms and indications. Abnormal sensations and symptoms of the disease are caused by the involvement of a specific receptor or molecular pathway and gene functions. These receptors or molecules may be stimulated or suppressed by environmental, natural or artificial agents. In such conditions, the administration of specific homoeopathic medicine having a similar kind of affinity towards the particular receptors or molecules involved in the disease process leads to modulation of such receptor or molecular pathways (e.g., desensitization, sensitization, inhibition). These kinds of actions cause the betterment of symptoms or curative effects. So “Similia similibus curantur” can be understood as a similar receptor or molecular pathway involved in both drug molecules biological/ pharmacological and toxicological action and disease pathogenesis". The selection of medicine is by comparing the similarity between the receptor or molecular pathway in disease pathogenesis and drug pathogenesis. To avoid unwanted aggravations or side effects while using mother tinctures or solutions, administer them less than their physiological dose. The theory of the pharmacological basis of Similia Similia Curantur creates a rational method to apply this Similia Principle. Based on this theory, there is a possibility of discovering Novel drugs in the future that acts and gives a cure in similia similibus curantur way.
Full-text available
Homeopathic arnica is widely believed to control bruising, reduce swelling and promote recovery after local trauma; many patients therefore take it perioperatively. To determine whether this treatment has any effect, we conducted a double-blind, placebo-controlled, randomized trial with three parallel arms. 64 adults undergoing elective surgery for carpal tunnel syndrome were randomized to take three tablets daily of homeopathic arnica 30C or 6C or placebo for seven days before surgery and fourteen days after surgery. Primary outcome measures were pain (short form McGill Pain Questionnaire) and bruising (colour separation analysis) at four days after surgery. Secondary outcome measures were swelling (wrist circumference) and use of analgesic medication (patient diary). 62 patients could be included in the intention-to-treat analysis. There were no group differences on the primary outcome measures of pain ( P=0.79) and bruising ( P=0.45) at day four. Swelling and use of analgesic medication also did not differ between arnica and placebo groups. Adverse events were reported by 2 patients in the arnica 6C group, 3 in the placebo group and 4 in the arnica 30C group. The results of this trial do not suggest that homeopathic arnica has an advantage over placebo in reducing postoperative pain, bruising and swelling in patients undergoing elective hand surgery.